Cantor Fitzgerald Comments on RNAC FY2026 Earnings

Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Cantor Fitzgerald issued their FY2026 earnings estimates for Cartesian Therapeutics in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings of ($3.84) per share for the year. The consensus estimate for Cartesian Therapeutics' current full-year earnings is $4.56 per share.

Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.07). The business had revenue of $1.10 million during the quarter, compared to the consensus estimate of $0.69 million.

Several other brokerages also recently commented on RNAC. Needham & Company LLC reduced their target price on shares of Cartesian Therapeutics from $41.00 to $40.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of Cartesian Therapeutics in a research report on Wednesday, April 9th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $43.00.

Cartesian Therapeutics Price Performance

Shares of Cartesian Therapeutics stock traded up $0.18 during midday trading on Tuesday, hitting $10.42. 45,404 shares of the company were exchanged, compared to its average volume of 114,065. The firm has a 50 day simple moving average of $10.58 and a 200-day simple moving average of $15.52. The firm has a market cap of $270.44 million, a P/E ratio of -0.20 and a beta of 0.33. Cartesian Therapeutics has a 52 week low of $8.46 and a 52 week high of $29.65.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. increased its position in Cartesian Therapeutics by 22.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,562 shares of the company's stock worth $82,000 after buying an additional 847 shares during the last quarter. Rhumbline Advisers lifted its holdings in Cartesian Therapeutics by 10.0% during the 4th quarter. Rhumbline Advisers now owns 10,201 shares of the company's stock valued at $183,000 after purchasing an additional 927 shares during the last quarter. Corebridge Financial Inc. boosted its position in Cartesian Therapeutics by 32.6% during the fourth quarter. Corebridge Financial Inc. now owns 5,122 shares of the company's stock worth $92,000 after purchasing an additional 1,258 shares during the period. Bank of New York Mellon Corp boosted its position in Cartesian Therapeutics by 7.9% during the first quarter. Bank of New York Mellon Corp now owns 20,937 shares of the company's stock worth $276,000 after purchasing an additional 1,530 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Cartesian Therapeutics by 44.8% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,786 shares of the company's stock valued at $104,000 after purchasing an additional 1,789 shares during the last quarter. Institutional investors and hedge funds own 86.95% of the company's stock.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.